Increased plasma cathepsin S and trombospondin-1 in patients with acute ST-segment elevation myocardial infarction
Abstract
Background: The role of cathepsins in the pathological progression of atherosclerotic lesions in ischemic heart disease have been defined in detail more than numerous times. This investigation examined the platelet-specific biomarker trombospondin-1 (TSP-1) and platelet function ex vivo, and compared this with cathepsin S (Cat-S; a biomarker unrelated to platelet activation but also associated this with increased mortality risk) in patients with ST-segment elevation myocardial infarction (STEMI).
Methods: The STEMI patients were divided into two groups depending on the degree of coronary vessel occlusion: those with closed (n = 90) and open culprit vessel (n = 40). Cat-S and TSP-1 were analyzed before, 1–3 days after and 3 months after percutanous coronary intervention (PCI).
Results: During acute STEMI, plasma TSP-1 was significantly elevated in patients with closed culprit lesions, but rapidly declined after PCI. In fact, TSP-1 after PCI was significantly lower inpatient samples compared to healthy individuals. In comparison, plasma Cat-S was significantly elevated both before and after PCI. In patients with closed culprit lesions, Cat-S was significantly higher compared to patients with open culprit lesions 3 months after PCI. Although troponin-I were higher (p < 0.01) in patients with closed culprit lesion, there was no correlation with Cat-S and TSP-1.
Conclusions: Cat-S but not TSP-1 may be a useful risk biomarker in relation to the severity of STEMI. However, the causality of Cat-S as a predictor for long-term mortality in STEMI remains to be ascertained in future studies.
Keywords: ST-segment elevation myocardial infarctioncathepsin Spercutaneous coronary interventionplatelets
References
- Li X, Liu Z, Cheng Z, et al. Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease. Chonnam Med J. 2012; 48(2): 77–85.
- Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010; 120(10): 3421–3431.
- Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012; 1824(1): 68–88.
- Cheng XWu, Shi GP, Kuzuya M, et al. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation. 2012; 125(12): 1551–1562.
- Kirschke H, Wiederanders B, Brömme D, et al. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J. 1989; 264(2): 467–473.
- Cheng XWu, Huang Z, Kuzuya M, et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension. 2011; 58(6): 978–986.
- Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev. 2005; 207: 229–241.
- Liu W, Spero DM. Cysteine protease cathepsin S as a key step in antigen presentation. Drug News Perspect. 2004; 17(6): 357–363.
- Lutgens SPM, Cleutjens KB, Daemen MJ, et al. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007; 21(12): 3029–3041.
- Pan L, Li Y, Jia L, et al. Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One. 2012; 7(4): e35315.
- Taleb S, Lacasa D, Bastard JP, et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J. 2005; 19(11): 1540–1542.
- Qin Y, Yang Y, Liu R, et al. Combined Cathepsin S and hs-CRP predicting inflammation of abdominal aortic aneurysm. Clin Biochem. 2013; 46(12): 1026–1029.
- de Nooijer R, Bot I, von der Thüsen JH, et al. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol. 2009; 29(2): 188–194.
- Ambily A, Kaiser WJ, Pierro C, et al. The role of plasma membrane STIM1 and Ca(2+)entry in platelet aggregation. STIM1 binds to novel proteins in human platelets. Cell Signal. 2014; 26(3): 502–511.
- Ji K, de Carvalho LP, Bi X, et al. Highly sensitive and quantitative human thrombospondin-1 detection by an M55 aptasensor and clinical validation in patients with atherosclerotic disease. Biosens Bioelectron. 2014; 55: 405–411.
- Marmagkiolis K, Feldman DN, Charitakis K. Thrombus Aspiration in STEMI. Curr Treat Options Cardiovasc Med. 2016; 18(1): 7.
- Wachtell K, Lagerqvist Bo, Olivecrona GK, et al. Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial. Curr Cardiol Rep. 2016; 18(1): 11.
- Soon K, Du HN, Klim S, et al. Non-ST elevation myocardial infarction with occluded artery and its clinical implications. Heart Lung Circ. 2014; 23(12): 1132–1140.
- Rodgers KJ, Watkins DJ, Miller AL, et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006; 26(4): 851–856.
- Galon MZ, Wang Z, Bezerra HG, et al. Differences determined by optical coherence tomography volumetric analysis in non-culprit lesion morphology and inflammation in ST-segment elevation myocardial infarction and stable angina pectoris patients. Catheter Cardiovasc Interv. 2015; 85(4): E108–E115.
- Ellulu MS, Patimah I, Khaza'ai H, et al. Atherosclerotic cardiovascular disease: a review of initiators and protective factors. Inflammopharmacology. 2016; 24(1): 1–10.
- Goel S, Miller A, Agarwal C, et al. Imaging Modalities to Identity Inflammation in an Atherosclerotic Plaque. Radiol Res Pract. 2015; 2015: 410967.
- Lv BJ, Lindholt JS, Cheng X, et al. Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study. PLoS One. 2012; 7(7): e41813.
- Chatzizisis YS, Baker AB, Sukhova GK, et al. Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation. 2011; 123(6): 621–630.
- Steubl D, Kumar SV, Tato M, et al. Circulating cathepsin-S levels correlate with GFR decline and sTNFR1 and sTNFR2 levels in mice and humans. Sci Rep. 2017; 7: 43538.
- Yan L, Ding S, Gu B, et al. Clinical application of simultaneous detection of cystatin C, cathepsin S, and IL-1 in classification of coronary artery disease. J Biomed Res. 2017; 31(4): 315–320.
- Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest. 1984; 74(5): 1764–1772.
- Vyas A, El Accaoui R, Blevins A, et al. Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. Postgrad Med. 2014; 126(5): 176–186.
- Wilhelmsen L. [ISIS-2--a study of patients with myocardial infarction. A combination of streptokinase and acetylsalicylic acid diminishes mortality risk, reinfarction and stroke]. Lakartidningen. 1988; 85(35): 2759–2764.
- Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998; 316(7141): 1337–1343.
- Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011; 306(24): 2704–2714.
- Grenegård M, Vretenbrant-Oberg K, Nylander M, et al. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. J Biol Chem. 2008; 283(27): 18493–18504.
